Prosetta's Board of Directors

Molly Coye, MD, MPH

Chairwoman of the Board of Directors, Prosetta Biosciences, Inc.

xmunroe@prosetta.com

Dr. Molly Joel Coye is the Chief Innovation Officer of UCLA Health and heads the Institute for Innovation in Health and the Global Lab for Innovation at UCLA, where she leads the health system in identifying new strategies, technologies, products and services to support the large-scale transformation of healthcare.  The Global Lab for Innovation advances the international exchange of health delivery innovations that enable dramatic improvements in access to and affordability of health services. 

Dr. Coye was previously the founder and CEO of the Health Technology Center (HealthTech), a non-profit education and research organization established in 2000 that became the premier forecasting organization for emerging technologies in health care. Dr. Coye is a member of the Institute of Medicine, of the Board of Directors of Aetna, Inc., Prosetta Biosciences, Inc., Big White Wall, the American Telemedicine Association, and the Advisory Board of ACCESS Health International. She previously served as Chair of the Board of Directors of PATH, one of the largest nonprofit organizations in global health, and on the boards of the American Hospital Association, the American
Public Health Association, and the China Medical Board.

 

 

Vishwanath R. Lingappa, MD, PhD

Chief Executive Officer, Chief Technology Officer and Member of the Board of Directors, Prosetta Biosciences, Inc.

Vishwanath R. Lingappa is CEO and CTO of Prosetta Biosciences, Inc., in San Francisco. In these roles he is responsible for the advancement of Prosetta’s scientific programs. He received a B.A. degree from Swarthmore College in 1975, his Ph.D. degree from The Rockefeller University in 1979, and M.D. degree from Cornell University Medical College in 1980. Dr. Lingappa completed residency training in Internal Medicine before joining the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF) in 1982, where he ran an NIH-funded basic research laboratory for over 20 years. It was during this time that the core discoveries on which Prosetta’s science is based were made and refined in his laboratory.

At UCSF he was heavily involved in medical student and resident teaching and training, and was author and co-editor of highly acclaimed textbooks in physiology, pathophysiology and cell biology. He has supervised some 40 pre and post-doctoral trainees, 8 of whom received the Ph.D. degree under his guidance. He has co-authored over 90 publications. He was promoted to Professor in 1991. Dr. Lingappa also practiced internal medicine at San Francisco General Hospital for over 26 years. He is recipient of a Kaiser Award for excellence in teaching (1990) and is a Fellow of the American Association for the Advancement of Science (2004). Dr. Lingappa is an Emeritus Professor of Physiology at UCSF.

 

Joseph "Mike" McCune, MD, PhD

Member of the Board of Directors, Prosetta Biosciences, Inc.

mike_mccune.jpg

Dr. McCune received the B.A. degree from Harvard College in 1975, M.D. from Cornell University Medical College in 1982, and Ph.D. from The Rockefeller University in 1982, followed by residency in internal medicine at UCSF and post-doctoral research at Stanford.  At Stanford he pioneered the SCIDhu mouse as a small animal model of HIV disease and co-founded SyStemix, a biotechnology company based substantially on his intellectual property, where he served as President and CEO and later, Scientific Director. After the acquisition of SyStemix by Sandoz in 1991 he joined the faculty at UCSF where he is now Chief of the Division of Experimental Medicine and a member of the Board of Directors of the UCSF Clinical and Translational Science Institute.  The current research focus of his laboratory is on understanding the correlates of protective immunity against HIV.  He has over 200 publications, and 20 patents issued or pending. He has been a practicing physician at the San Francisco General Hospital AIDS clinic for the past 24 years.

Dr. McCune’s studies have led to the publication of over 170 peer-reviewed articles and he is the holder of 20 patents and inventions. He is a member of many scientific and professional societies, including the American Society for Clinical Investigation, the American Association of Physicians, and the Henry Kunkel Society. He has served on the editorial boards of Virology and the Journal of the Acquired Immune Deficiency Syndrome. On the basis of this work, he was awarded the Elizabeth Glaser Pediatric AIDS Foundation Scientist Award in 1996, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research in 2000, a MERIT Award from the NIH in 2001, the NIH Director’s Pioneer Award in 2004, and a number of mentoring awards for his activities with junior faculty, postdoctoral fellows, and graduate students.

 

Karl Manheim, BS, JD, LLM

Member of the Board of Directors, Prosetta Biosciences, Inc.

Karl Manheim is a Professor of Law at Loyola Law School (Los Angeles) where he teaches Constitutional Law, International Patent Law and various technology courses. In 2007 he was special counsel to the U.S. House of Representatives Committee on the Judiciary, Subcommittee on Courts, the Internet and Intellectual Property. Between 1999 and 2006, Prof. Manheim was Co-Director of the Program for Law and Technology at the California Institute of Technology and Loyola Law School. He has taught at the University of Southern California, the University of International Business and Economics (Beijing) and the University of Bologna, and has guest lectured at Harvard College, CalTech and UCLA.

Prof. Manheim was admitted to the California Bar in 1974, the United States Patent Bar in 1980, and the United States Supreme Court in 1984. He holds a Bachelor of Science degree (Physics) from Bradley University, a Juris Doctor degree from Northeastern University Law School, and a Masters of Law degree from Harvard Law School.
He is a co-founder of Prosetta Biosciences, Inc.


Thomas Higgins

Member of the Board of Directors, Prosetta Biosciences, Inc.

thomas_higgins.jpg

Thomas Higgins was the founding chief executive and is a director at Prosetta Biosciences, Inc. He served as the president and CEO from 2003-2008. Prior to that, he was president and chief operating officer of Business for Social Responsibility. BSR is the leading global resource for businesses seeking to improve their performance in areas of corporate social responsibility.

Higgins served in the administration of President Carter, beginning as a senior executive at HEW, where he was Director of Region VII, and at HHS, as Associate Commissioner of the Social Security Administration. His service culminated as a presidential appointee on the White House Senior Staff, where he served as Deputy Secretary to the Cabinet. He was elected to the Iowa General Assembly in 1972, where he served three terms and was chairman of the Human Resources Committee, before resigning to serve in the Carter administration. In the early 1980s he was the head of the Health and Social Services Department in Portland, Oregon.

In 1983, he began his private sector career as founding Publisher and President of The Business Journal in Portland, published by American Cities Business Journals. Subsequently, Higgins became the co-founder and editor-in-chief of HealthWeek, a national newspaper covering health business news in the United States, published by CMP Publications. In 1990, Higgins was recruited as a vice president of Blue Cross/Blue Shield of Maryland. He was subsequently elected a Senior Vice President of the company, with broad responsibilities for operations and staff organizations.

Higgins was subsequently a senior vice president of Edison International and its subsidiary, Southern California Edison. Edison is a $15 billion power generation and electric distribution company. During his career with the company, Higgins served on the management committee and helped to set overall strategy for the company. He had responsibility for several staff functions and was president of Edison Enterprises, an unregulated subsidiary.

Higgins has a distinguished record of community service. He currently serves on the boards of directors of Scan Health Plan, a non-profit Medicare Advantage Plan serving California and Arizona residents; St. Ambrose University, where he graduated cum laude in 1967; The Zen Hospice Project; The Coalition to Transform Advanced Care; and The SCAN Foundation. In addition, his corporate boards include Amber Kinetics, an energy storage company,  Akonni Biosystems, and IIC, an energy software company.

 

Abel Weinrib, BS, PhD

Member of the Board of Directors, Prosetta Biosciences, Inc.

Dr. Abel Weinrib held a number of officer positions with Intel Corporation from 1994 until he retired from the company in 2010, most recently as Vice President and Director of Intel Corporation’s Corporate Technology Group, Intel’s central research and development organization with about 900 employees across 10 sites worldwide, responsible for Intel’s research and technology innovation. Under Abel's leadership, the Group established a highly productive pipeline from early-stage research to substantial product impact across all of Intel's businesses. Previously, Abel was responsible for driving Intel's leadership in communications and networking technologies as Director of the Communications Technology Lab. Before joining Intel in 1994, he was Member of Technical Staff at Bell Communications Research, conducting research for the regional Bell Telephone companies on Internet and communications technologies. From 1994 to 2001, he served as Executive Director of the Internet Architecture Board and from 1995 to 1999 was Chair of the Internet Research Task Force. He has published broadly in the fields of networking and communications.

Abel received his bachelor's degree from MIT in 1979 and his Ph.D. from Harvard University in 1983, both in physics.

 

David N. Keys

Member of the Board of Directors, Prosetta Biosciences, Inc.

David Keys joined our Board of Directors in 2012.  David currently serves as an Independent Financial and Operations Consultant.  His current engagements include financial and operational oversight of a substantial real estate holdings, development and investment company, including significant ranch and farming operations.  In addition, he currently oversees a substantial investment portfolio consisting of a number of startup and early stage companies.  David began his career with Deloitte (one of the now Big 4 accounting firms) serving in the audit group in the Las Vegas and New York City executive offices.  David was the Executive Vice President and CFO of American Pacific Corporation, a publicly traded chemical company for a number of years.  Mr. Keys has served on the Boards of Directors of two publicly traded companies, AmFed Financial (NASDAQ) and American Pacific Corporation (NASDAQ).  He was a member of the executive committee of the American Pacific Board of Directors.  David has also been a member of the Boards of Directors of Norwest Bank of Nevada and Wells Fargo Bank of Nevada. He currently serves on the Board of Directors of several privately held companies including Akonni Biosystems Inc. (Audit Committee Chair), Paywall Inc., Skywire Media Inc. (Chairman of the Board and Interim CEO) and Walker Digital Table Systems, LLC.  David is a Certified Public Accountant (CPA), Certified Valuation Analyst (CVA), Certified Management Accountant (CMA), Certified in Financial Forensics (CFF), Chartered Global Management Accountant (CGMA), Certified Information Technology Professional (CITP) and a Certified Financial Manager (CFM).  Mr. Keys is a member of the National Roster of Neutrals (sometimes referred to as the Commercial Panel) of the American Arbitration Association and has served as the sole arbitrator and as a member of a panel of three arbitrators on several cases, principally involving contract and valuation disputes.  He received a BS-Accounting degree from Oklahoma State University in 1978.

 

Phil Satow

Member of the Board of Directors, Prosetta Biosciences, Inc.

Phil Satow and his family founded The Jed Foundation in 2000 after the loss of their son, Jed, to suicide. Phil serves as Chair of the Board of Directors of The Jed Foundation and is Co-Chair of the Research Task Force for Suicide Research Prioritization for the National Action Alliance for Suicide Prevention (NAASP), as well as a member of the board of directors for the American Foundation for Suicide Prevention. Phil has also served as a member of the Executive Committee of the NAASP. Phil and his wife Donna were honored with the HOPE Award for Depression Advocacy from the Hope for Depression Research Foundation in 2012, and have received the annual award of the Mental Health Association of Westchester.

Phil is Chairman of the Board of Directors at Nutrition 21, a leader in the nutritional supplement industry, and has more than 30 years of experience in the pharmaceutical industry. He was Co-founder, Chairman and CEO of JDS Pharmaceuticals, a specialty pharmaceutical company focused on the psychiatry and women’s health markets. Prior to founding JDS, Phil served as Executive Vice President of Forest Laboratories, President of Forest Pharmaceuticals and as a member of the Forest Board of Directors. Before joining Forest, he served as Vice President and General Manager of the Wallace Laboratories Division of Carter–Wallace. In addition, he has held a variety of executive positions at Pfizer. Phil has also served on the public boards of directors of Crucell, Eyetech and Noven, as well as various others. Phil graduated from Columbia College and has an MA in Economics from Georgetown University.

 

CJ Sylvester

Member of the Board of Directors, Prosetta Biosciences, Inc.

Mr. Sylvester is a Vice President and Analyst covering the health care sector for Fred Alger Management, Inc.  Prior to joining Alger in 2014, Mr. Sylvester has worked as an analyst for Catapult, Lombard Odier Investment Management, Diamondback Capital Advisers LLC, UBS Wealth Management, Banc of America Securities, Schwab Soundview Capital Markets and UBS Investment Bank.  Mr. Sylvester has spent 18 years covering the healthcare industry and was consistently ranked as one of the top ranked sellside analysts prior to joining the buyside in 2005. Mr. Sylvester graduated from Bucknell University and holds an M.S. in Neurobiology and Neuroscience from the College of William and Mary. He currently resides in Wilton, Connecticut with his wife of 14 years and their 4 children.